SRC and neoplasm: Despite the anti-tumoral effects of c-Src inhibitors reported in pre-clinical studies [75,76,77,78] the controversial outcomes of recent clinical trials highlighted the need to identify novel predictive biomarkers of tumor response to c-Src inhibitors.